Symbols / TRVI
TRVI Chart
About
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.45B |
| Enterprise Value | 1.25B | Income | -45.86M | Sales | — |
| Book/sh | 1.48 | Cash/sh | 1.52 | Dividend Yield | — |
| Payout | 0.00% | Employees | 34 | IPO | — |
| P/E | — | Forward P/E | -25.21 | PEG | — |
| P/S | — | P/B | 7.62 | P/C | — |
| EV/EBITDA | -24.46 | EV/Sales | — | Quick Ratio | 21.69 |
| Current Ratio | 21.93 | Debt/Eq | 0.43 | LT Debt/Eq | — |
| EPS (ttm) | -0.37 | EPS next Y | -0.45 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-17 | ROA | -23.93% |
| ROE | -36.87% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 128.23M |
| Shs Float | 103.76M | Short Float | 13.90% | Short Ratio | 10.42 |
| Short Interest | — | 52W High | 14.39 | 52W Low | 4.09 |
| Beta | 0.96 | Avg Volume | 1.76M | Volume | 1.12M |
| Target Price | $21.55 | Recom | Strong_buy | Prev Close | $11.10 |
| Price | $11.28 | Change | 1.62% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$21.55
Mean price target
2. Current target
$11.28
Latest analyst target
3. DCF / Fair value
$-4.05
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$11.28
Low
$16.00
High
$27.00
Mean
$21.55
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-09 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2026-01-08 | main | D. Boral Capital | Buy → Buy | $19 |
| 2025-12-19 | main | Stifel | Buy → Buy | $18 |
| 2025-11-20 | main | Leerink Partners | Outperform → Outperform | $16 |
| 2025-11-14 | main | D. Boral Capital | Buy → Buy | $19 |
| 2025-11-14 | main | Oppenheimer | Outperform → Outperform | $24 |
| 2025-11-14 | main | Morgan Stanley | Overweight → Overweight | $19 |
| 2025-11-14 | main | Clear Street | Buy → Buy | $21 |
| 2025-08-21 | init | Morgan Stanley | — → Overweight | $18 |
| 2025-08-08 | main | Raymond James | Strong Buy → Strong Buy | $27 |
| 2025-08-08 | main | Needham | Buy → Buy | $22 |
| 2025-07-01 | init | Cantor Fitzgerald | — → Overweight | $25 |
| 2025-06-02 | main | D. Boral Capital | Buy → Buy | $21 |
| 2025-05-28 | init | HC Wainwright & Co. | — → Buy | $21 |
| 2025-05-20 | reit | Needham | Buy → Buy | $24 |
| 2025-04-08 | reit | Needham | Buy → Buy | $24 |
| 2025-03-19 | reit | B. Riley Securities | Buy → Buy | $20 |
| 2025-03-19 | main | Needham | Buy → Buy | $24 |
| 2025-03-19 | main | D. Boral Capital | Buy → Buy | $21 |
| 2025-03-19 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
- Does Trevi Therapeutics (TRVI) Have the Potential to Rally 102.07% as Wall Street Analysts Expect? - Finviz Mon, 23 Feb 2026 15
- Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates - PR Newswire hu, 13 Nov 2025 08
- Discipline and Rules-Based Execution in TRVI Response - Stock Traders Daily Sat, 21 Feb 2026 19
- Trevi Therapeutics Executives to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference - Quiver Quantitative ue, 17 Feb 2026 12
- Haduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan Stanley - Yahoo Finance hu, 11 Sep 2025 07
- TRVI Stock Falls -15% With A 7-day Losing Spree On Technical Breakdown - Trefis ue, 06 Jan 2026 08
- Tejara Capital Ltd Trims Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat Sun, 01 Feb 2026 08
- Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Exploring a 72% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews Fri, 19 Dec 2025 08
- Trevi Therapeutics stock hits all-time high of 14.01 USD - Investing.com Wed, 10 Dec 2025 08
- Did JAMA-Published CORAL Data on Nalbuphine ER Just Shift Trevi Therapeutics' (TRVI) Investment Narrative? - simplywall.st Mon, 02 Feb 2026 08
- Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer - PR Newswire hu, 04 Dec 2025 08
- Trend Tracker for (TRVI) (TRVI:CA) - Stock Traders Daily Mon, 16 Feb 2026 17
- Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Brokerages - MarketBeat Fri, 06 Feb 2026 08
- How Trevi Therapeutics’ (TRVI) Phase 3 Progress and Fresh Funding May Influence Investor Expectations - Yahoo Finance Fri, 14 Nov 2025 08
- Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock - PR Newswire ue, 03 Jun 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4225 | 2159 | — | Conversion of Exercise of derivative security at price 0.51 per share. | GALLETTA CHRISTOPHER | Officer | — | 2025-12-02 00:00:00 | D |
| 1 | 1851852 | 2537037 | — | Conversion of Exercise of derivative security at price 1.37 per share. | BASKETT FOREST | Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-17 00:00:00 | I |
| 2 | 1851852 | 2537037 | — | Conversion of Exercise of derivative security at price 1.37 per share. | WALKER PAUL EDWARD | Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-17 00:00:00 | I |
| 3 | 1851852 | 2537037 | — | Conversion of Exercise of derivative security at price 1.37 per share. | FLORENCE ANTHONY A JR | Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-17 00:00:00 | I |
| 4 | 1851852 | 2537037 | — | Conversion of Exercise of derivative security at price 1.37 per share. | BEHBAHANI ALI | Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-17 00:00:00 | I |
| 5 | 1851852 | 2537037 | — | Conversion of Exercise of derivative security at price 1.37 per share. | MAKHZOUMI MOHAMAD | Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-17 00:00:00 | I |
| 6 | 1851852 | 2537037 | — | Conversion of Exercise of derivative security at price 1.37 per share. | NEW ENTERPRISE ASSOCIATES 16, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-17 00:00:00 | I |
| 7 | 1851852 | 2537037 | — | Conversion of Exercise of derivative security at price 1.37 per share. | CHANG CARMEN | Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-17 00:00:00 | I |
| 8 | 1851852 | 2537037 | — | Conversion of Exercise of derivative security at price 1.37 per share. | SANDELL SCOTT D | Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-17 00:00:00 | I |
| 9 | 2631 | 17365 | — | Sale at price 6.60 per share. | SCIASCIA THOMAS R | Officer | — | 2025-03-25 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | -147.00 | 82.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -47.79M | -28.58M | -27.84M | -32.79M |
| TotalUnusualItems | -147.00K | 82.00K | ||
| TotalUnusualItemsExcludingGoodwill | -147.00K | 82.00K | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -47.91M | -29.07M | -29.15M | -33.94M |
| ReconciledDepreciation | 147.00K | 123.00K | 43.00K | 50.00K |
| EBITDA | -47.79M | -28.58M | -27.98M | -32.71M |
| EBIT | -47.94M | -28.71M | -28.02M | -32.76M |
| NetInterestIncome | 3.60M | 4.36M | 577.00K | -1.19M |
| InterestExpense | 4.00K | 391.00K | 1.16M | 1.20M |
| InterestIncome | 3.60M | 4.75M | 1.74M | 10.00K |
| NormalizedIncome | -47.91M | -29.07M | -29.01M | -34.02M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -47.91M | -29.07M | -29.15M | -33.94M |
| TotalExpenses | 51.52M | 33.92M | 29.91M | 32.48M |
| TotalOperatingIncomeAsReported | -51.52M | -33.92M | -29.91M | -32.48M |
| DilutedAverageShares | 101.97M | 99.03M | 64.54M | 22.84M |
| BasicAverageShares | 101.97M | 99.03M | 64.54M | 22.84M |
| DilutedEPS | -0.47 | -0.29 | -0.45 | -1.49 |
| BasicEPS | -0.47 | -0.29 | -0.45 | -1.49 |
| DilutedNIAvailtoComStockholders | -47.91M | -29.07M | -29.15M | -33.94M |
| NetIncomeCommonStockholders | -47.91M | -29.07M | -29.15M | -33.94M |
| NetIncome | -47.91M | -29.07M | -29.15M | -33.94M |
| NetIncomeIncludingNoncontrollingInterests | -47.91M | -29.07M | -29.15M | -33.94M |
| NetIncomeContinuousOperations | -47.91M | -29.07M | -29.15M | -33.94M |
| TaxProvision | -30.00K | -32.00K | -36.00K | -21.00K |
| PretaxIncome | -47.94M | -29.10M | -29.19M | -33.96M |
| OtherIncomeExpense | -15.00K | 469.00K | 142.00K | -293.00K |
| OtherNonOperatingIncomeExpenses | -15.00K | 469.00K | 289.00K | -375.00K |
| GainOnSaleOfSecurity | -147.00K | 82.00K | ||
| NetNonOperatingInterestIncomeExpense | 3.60M | 4.36M | 577.00K | -1.19M |
| TotalOtherFinanceCost | 383.00K | 474.00K | ||
| InterestExpenseNonOperating | 4.00K | 391.00K | 1.16M | 1.20M |
| InterestIncomeNonOperating | 3.60M | 4.75M | 1.74M | 10.00K |
| OperatingIncome | -51.52M | -33.92M | -29.91M | -32.48M |
| OperatingExpense | 51.52M | 33.92M | 29.91M | 32.48M |
| ResearchAndDevelopment | 39.38M | 23.68M | 19.83M | 22.98M |
| SellingGeneralAndAdministration | 12.15M | 10.24M | 10.07M | 9.49M |
| GeneralAndAdministrativeExpense | 12.15M | 10.24M | 10.07M | 9.49M |
| OtherGandA | 12.15M | 10.24M | 10.07M | 9.49M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 93.60M | 68.28M | 59.94M | 28.51M |
| ShareIssued | 93.60M | 68.28M | 59.94M | 28.51M |
| TotalDebt | 1.03M | 1.34M | 9.18M | 14.63M |
| TangibleBookValue | 99.64M | 82.55M | 107.46M | 17.07M |
| InvestedCapital | 99.64M | 82.55M | 116.61M | 31.56M |
| WorkingCapital | 98.92M | 81.72M | 109.22M | 25.23M |
| NetTangibleAssets | 99.64M | 82.55M | 107.46M | 17.07M |
| CapitalLeaseObligations | 1.03M | 1.34M | 27.00K | 144.00K |
| CommonStockEquity | 99.64M | 82.55M | 107.46M | 17.07M |
| TotalCapitalization | 99.64M | 82.55M | 109.61M | 25.73M |
| TotalEquityGrossMinorityInterest | 99.64M | 82.55M | 107.46M | 17.07M |
| StockholdersEquity | 99.64M | 82.55M | 107.46M | 17.07M |
| GainsLossesNotAffectingRetainedEarnings | 61.00K | -29.00K | -122.00K | 0.00 |
| OtherEquityAdjustments | 61.00K | -29.00K | -122.00K | |
| RetainedEarnings | -287.05M | -239.13M | -210.07M | -180.92M |
| AdditionalPaidInCapital | 386.53M | 321.64M | 317.59M | 197.96M |
| CapitalStock | 94.00K | 68.00K | 60.00K | 29.00K |
| CommonStock | 94.00K | 68.00K | 60.00K | 29.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 11.26M | 6.86M | 15.56M | 21.40M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 747.00K | 1.03M | 2.16M | 8.68M |
| OtherNonCurrentLiabilities | 3.00K | |||
| DerivativeProductLiabilities | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 747.00K | 1.03M | 2.15M | 8.68M |
| LongTermCapitalLeaseObligation | 747.00K | 1.03M | 2.00K | 24.00K |
| LongTermDebt | 2.15M | 8.65M | ||
| CurrentLiabilities | 10.51M | 5.82M | 13.40M | 12.72M |
| OtherCurrentLiabilities | 114.00K | |||
| CurrentDebtAndCapitalLeaseObligation | 285.00K | 306.00K | 7.03M | 5.95M |
| CurrentCapitalLeaseObligation | 285.00K | 306.00K | 25.00K | 120.00K |
| CurrentDebt | 7.00M | 5.83M | ||
| OtherCurrentBorrowings | 7.00M | 5.83M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.54M | 1.61M | 1.51M | 1.25M |
| PayablesAndAccruedExpenses | 7.69M | 3.90M | 4.87M | 5.41M |
| CurrentAccruedExpenses | 4.27M | 2.10M | 2.01M | 2.56M |
| Payables | 3.41M | 1.81M | 2.86M | 2.85M |
| AccountsPayable | 3.41M | 1.81M | 2.86M | 2.85M |
| TotalAssets | 110.90M | 89.40M | 123.02M | 38.48M |
| TotalNonCurrentAssets | 1.47M | 1.86M | 399.00K | 518.00K |
| OtherNonCurrentAssets | 243.00K | 297.00K | 205.00K | 334.00K |
| NetPPE | 1.23M | 1.56M | 194.00K | 184.00K |
| AccumulatedDepreciation | -228.00K | -134.00K | -225.00K | -182.00K |
| GrossPPE | 1.46M | 1.69M | 419.00K | 366.00K |
| Leases | 29.00K | 29.00K | 130.00K | 130.00K |
| ConstructionInProgress | 7.00K | 17.00K | 53.00K | 0.00 |
| OtherProperties | 1.07M | 1.34M | 24.00K | 131.00K |
| MachineryFurnitureEquipment | 349.00K | 304.00K | 212.00K | 105.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 109.43M | 87.55M | 122.62M | 37.96M |
| OtherCurrentAssets | 867.00K | 955.00K | 1.31M | 241.00K |
| PrepaidAssets | 939.00K | 3.62M | 795.00K | 886.00K |
| Receivables | 241.00K | |||
| TaxesReceivable | 241.00K | |||
| CashCashEquivalentsAndShortTermInvestments | 107.62M | 82.97M | 120.51M | 36.83M |
| OtherShortTermInvestments | 73.53M | 50.57M | 107.92M | 0.00 |
| CashAndCashEquivalents | 34.10M | 32.40M | 12.59M | 36.83M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -38.29M | -31.85M | -28.33M | -28.95M |
| RepaymentOfDebt | -126.00K | -9.50M | -5.83M | 0.00 |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 61.15M | 1.71M | 105.41M | 21.18M |
| CapitalExpenditure | -35.00K | -137.00K | -159.00K | |
| InterestPaidSupplementalData | 4.00K | 331.00K | 594.00K | 603.00K |
| EndCashPosition | 34.10M | 32.40M | 12.59M | 36.83M |
| BeginningCashPosition | 32.40M | 12.59M | 36.83M | 45.00M |
| ChangesInCash | 1.70M | 19.81M | -24.24M | -8.17M |
| FinancingCashFlow | 61.48M | -7.91M | 111.31M | 20.77M |
| CashFlowFromContinuingFinancingActivities | 61.48M | -7.91M | 111.31M | 20.77M |
| NetOtherFinancingCharges | -258.00K | -247.00K | -450.00K | |
| ProceedsFromStockOptionExercised | 464.00K | 142.00K | 11.98M | 42.00K |
| NetCommonStockIssuance | 61.15M | 1.71M | 105.41M | 21.18M |
| CommonStockIssuance | 61.15M | 1.71M | 105.41M | 21.18M |
| NetIssuancePaymentsOfDebt | -126.00K | -9.50M | -5.83M | 0.00 |
| NetShortTermDebtIssuance | 0.00 | -9.41M | ||
| ShortTermDebtPayments | 0.00 | -9.41M | ||
| NetLongTermDebtIssuance | -126.00K | -9.50M | -5.83M | 0.00 |
| LongTermDebtPayments | -126.00K | -9.50M | -5.83M | 0.00 |
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -21.53M | 59.43M | -107.37M | 0.00 |
| CashFlowFromContinuingInvestingActivities | -21.53M | 59.43M | -107.37M | 0.00 |
| NetInvestmentPurchaseAndSale | -21.49M | 59.56M | -107.21M | 0.00 |
| SaleOfInvestment | 76.97M | 69.50M | 19.00M | 0.00 |
| PurchaseOfInvestment | -98.46M | -9.93M | -126.22M | 0.00 |
| NetPPEPurchaseAndSale | -35.00K | -137.00K | -159.00K | 0.00 |
| PurchaseOfPPE | -35.00K | -137.00K | -159.00K | 0.00 |
| OperatingCashFlow | -38.26M | -31.71M | -28.18M | -28.95M |
| CashFlowFromContinuingOperatingActivities | -38.26M | -31.71M | -28.18M | -28.95M |
| ChangeInWorkingCapital | 6.83M | -3.85M | -1.23M | 1.51M |
| ChangeInPayablesAndAccruedExpense | 4.17M | -997.00K | -630.00K | 1.17M |
| ChangeInAccruedExpense | 2.56M | 52.00K | -639.00K | 336.00K |
| ChangeInPayable | 1.60M | -1.05M | 9.00K | 831.00K |
| ChangeInAccountPayable | 1.60M | -1.05M | 9.00K | 831.00K |
| ChangeInPrepaidAssets | 2.66M | -2.85M | -601.00K | 342.00K |
| OtherNonCashItems | 460.00K | 947.00K | 520.00K | 974.00K |
| StockBasedCompensation | 3.59M | 2.25M | 2.33M | 2.54M |
| AssetImpairmentCharge | 0.00 | 390.00K | 0.00 | |
| AmortizationOfSecurities | -1.37M | -2.12M | -829.00K | 0.00 |
| DepreciationAmortizationDepletion | 147.00K | 123.00K | 43.00K | 50.00K |
| DepreciationAndAmortization | 147.00K | 123.00K | 43.00K | 50.00K |
| Depreciation | 43.00K | 50.00K | ||
| OperatingGainsLosses | 10.00K | 147.00K | -82.00K | |
| GainLossOnInvestmentSecurities | 147.00K | -82.00K | ||
| GainLossOnSaleOfPPE | 0.00 | 10.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -47.91M | -29.07M | -29.15M | -33.94M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TRVI
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|